Benzyloxycarbonyl-4-oxo-prolin | 105903-44-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Benzyloxycarbonyl-4-oxo-prolin
• 英文别名: 4-oxo-1-(benzyloxycarbonyl)pyrrolidine-(S)-2-carboxylic acid；4-keto-1[(phenylmethoxy)carbonyl]-L-proline；1-benzyloxycarbonyl-4-oxoproline；1-((Benzyloxy)carbonyl)-4-oxopyrrolidine-2-carboxylic acid；4-oxo-1-phenylmethoxycarbonylpyrrolidine-2-carboxylic acid
• CAS: 105903-44-4
• 化学式: C₁₃H₁₃NO₅
• 分子量: 263.25
• InChiKey: RPLLCMZOIFOBIF-UHFFFAOYSA-N

物化性质

• 沸点：
  488.5±45.0 °C(Predicted)
• 密度：
  1.408±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  83.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  甲醇 、 Benzyloxycarbonyl-4-oxo-prolin 在 盐酸 作用下， 反应 0.5h， 生成 1-benzyloxycarbonyl-4,4-dimethoxyproline methyl ester
  参考文献：
  名称：

  INHIBITORS OF ALPHA-L BETA-2 MEDIATED CELL ADHESION

  摘要：

  公开号：

  EP1307455B1

文献信息

• [EN] HEPATITIS C VIRUS INHIBITORS<br/>[FR] INHIBITEURS DU VIRUS DE L'HÉPATITE C
  申请人：ENANTA PHARM INC

  公开号：WO2015017382A1

  公开（公告）日：2015-02-05

  The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: (structurally represented), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明公开了化合物的结构式(I)及其药学上可接受的盐、酯或前药：（结构表示），这些化合物抑制RNA含量病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。
• Process and intermediates for preparing 4-substituted proline derivatives
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04734508A1

  公开（公告）日：1988-03-29

  A process is provided for preparing 4-hydroxy-4-phenyl-proline derivatives of the structure ##STR1## wherein R.sub.1 is a nitrogen protecting group such as benzoyl, benzyloxycarbonyl, t-butoxycarbonyl, benzyl, benzhydryl, trityl, acetyl, trifluoromethylacetyl, sulfonamides, and the like and wherein X is OR.sub.2 and R.sub.2 is hydrogen or an acid protecting group such as lower alkyl, aryl-lower alkyl or a metal ion, such as Na or K, or X is NR.sub.3 R.sub.4 wherein R.sub.3 and R.sub.4 may be the same or different and are hydrogen, lower alkyl, aryl or arylalkyl, or R.sub.3 and R.sub.4 together with the nitrogen to which they are attached form a 5-, 6- or 7-membered ring. The process includes the steps of forming triphenylcerium [(C.sub.6 H.sub.5).sub.3 Ce], for example, by reacting cerium trichloride (CeCl.sub.3) with phenyllithium, and reacting the triphenylcerium with the keto acid ##STR2## in the presence of an inert organic solvent such as tetrahydrofuran. The 4-hydroxy-4-phenyl-proline derivatives used in the preparation of 4-substituted proline derivatives which are employed for preparing certain angiotensin-converting enzyme inhibitors.

  提供了一种制备4-羟基-4-苯基-脯氨酸衍生物的方法，其结构为##STR1##其中R.sub.1是氮保护基，例如苯甲酰、苄氧羰基、t-叔丁氧羰基、苄基、苯甲基、三苯甲基、乙酰、三氟甲基乙酰、磺酰胺等，其中X为OR.sub.2，R.sub.2为氢或酸保护基，例如较低的烷基、芳基-较低的烷基或金属离子，例如Na或K，或者X为NR.sub.3R.sub.4，其中R.sub.3和R.sub.4可以相同或不同，分别为氢、较低的烷基、芳基或芳基烷基，或R.sub.3和R.sub.4与它们连接的氮一起形成5、6或7元环。该方法包括以下步骤：通过将三苯基铈[(C.sub.6H.sub.5).sub.3Ce]与酮酸##STR2##在惰性有机溶剂（例如四氢呋喃）的存在下反应形成三苯基铈，例如通过将三氯化铈（CeCl.sub.3）与苯基锂反应。用于制备某些血管紧张素转化酶抑制剂的4-羟基-4-苯基-脯氨酸衍生物用于制备4-取代的脯氨酸衍生物。
• [EN] NOVEL BENZIMIDAZOLE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE BENZIMIDAZOLE
  申请人：ENANTA PHARM INC

  公开号：WO2013052369A1

  公开（公告）日：2013-04-11

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了式（I）的化合物，或其药学上可接受的盐、酯或前药：其抑制RNA含量的病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。本发明还涉及包含上述化合物的制药组合物，用于治疗患有HCV感染的受试者。本发明还涉及通过给受试者注射包含本发明化合物的制药组合物来治疗HCV感染的方法。
• [EN] AROMATIC AMIDINE DERIVATIVES USEFUL AS SELECTIVE THROMBIN INHIBITORS<br/>[FR] DERIVES D'AMIDINE AROMATIQUE UTILES EN TANT QU'INHIBITEURS SELECTIFS DE LA THROMBINE
  申请人：C & C RESEARCH LABORATORIES

  公开号：WO1997045424A1

  公开（公告）日：1997-12-04

  (EN) The present invention relates to a novel thrombin inhibitor which is effective even when orally administered. More specifically, the present invention relates to an aromatic amidine derivative represented by formula (I) and the salts thereof, which show potent selective inhibitory activity for thrombin in which (a), R, R1, R2, R3, A, W, Y and n are defined as described in the specification.(FR) L'invention concerne un nouvel inhibiteur de la thrombine qui est efficace même lorsqu'il est administré par voie orale. Plus spécifiquement, l'invention concerne un dérivé d'amidine aromatique représenté par la formule (I) et des sels de celle-ci, qui présentent une activité inhibitrice sélective pour la thrombine. Dans ladite formule, (a), R, R1, R2, R3 A, W, Y et n sont définis comme décrits dans la spécification.

  本发明涉及一种新型的抑制凝血酶的药物，即使口服也具有有效性。更具体地说，本发明涉及一种芳香基脒衍生物及其盐，其在(a)、R、R1、R2、R3、A、W、Y和n如规范所述的情况下，对凝血酶具有强有力的选择性抑制活性。
• Inhibitors of alphaLbeta2 mediated cell adhesion
  申请人：Sircar Ila

  公开号：US20050148602A1

  公开（公告）日：2005-07-07

  The present invention relates to a compound of the following formula: or a pharmaceutically acceptable salt thereof. Also disclosed are compositions containing the compound and methods of preparing and using the compounds. The compounds of the invention are useful in treating α L β 2 adhesion mediated conditions in a mammal.

  本发明涉及以下式的化合物：或其药学上可接受的盐。本发明还公开了含有该化合物的组合物以及制备和使用该化合物的方法。本发明的化合物在治疗哺乳动物的αLβ2粘附介导的疾病方面是有用的。